0001104659-26-055322
SEC filingRevenue grew 7.8% to $34.5M driven by clinic expansion, with gross profit up 2.6% to $16.2M despite mix-driven margin contraction to 46.9%, narrowing operating losses 18.3% to -$9.0M amid post-acquisition efficiencies, though cash burn and covenant risks persist.
Revenue rose 7.8% year-over-year to $34.5 million in Q1 FY2026 from $32.0 million, reflecting contributions from clinic expansion following the Greenbrook acquisition. This growth occurred despite a shift in revenue mix within the Clinic segment, which drove gross margin contraction to 46.9% from higher prior levels, with gross profit increasing modestly 2.6% to $16.2 million. Management notes that gross margins are influenced by product sales mix, pricing, and third-party manufacturing costs, consistent with historical patterns.
Operating loss narrowed significantly by 18.3% to -$9.0 million from -$11.0 million, as the company realized early cost efficiencies post-acquisition. Management anticipates further sales and marketing expense reductions in 2026 relative to 2025 across these divisions, supporting ongoing efforts to improve profitability amid continued investments in commercial activities, market research, personnel costs including commissions, and share-based compensation. Net loss improved 14.9% to -$10.8 million, with diluted EPS at -$0.16 compared to -$0.21, highlighting progress in loss containment.
Cash flow from operating activities showed marked improvement, using -$9.4 million versus -$17.0 million prior year, aided by the lower net loss and favorable working capital movements. The decrease in net operating assets stemmed primarily from reductions in accrued expenses and an increase in prepaid commission expense, partially offset by lower accounts receivable. These shifts reflect operational adjustments post-acquisition, though the company maintains negative cash flows consistent with its history of operating losses since inception.
Looking forward, management expects operating losses to persist in the near term due to investments in sales, marketing, and product development. Credit facility covenants, including liquidity and trailing twelve-month minimum revenue requirements, pose risks; while compliant in Q1 post-amendment, a projected revenue shortfall by March 2027 could trigger a lender call. In such a scenario, the company lacks projected liquidity to repay the facility, underscoring vulnerability despite mitigation efforts like revenue cycle enhancements and device sales acceleration. Post-acquisition synergies remain critical for covenant compliance and a sustainable path to breakeven.